Key result
Transcatheter valve-in-valve procedures for structural valve deterioration in Mitroflow bioprostheses resulted in 10% in-hospital mortality and a cumulative survival of 90.9% at 1 year.
Why the study?
Does transcatheter valve-in-valve replacement using balloon-expandable bioprostheses provide safe and effective outcomes in patients with structural valve deterioration of Mitroflow bioprostheses?
Observational (n=11)
Does transcatheter valve-in-valve replacement using balloon-expandable bioprostheses provide safe and effective outcomes in patients with structural valve deterioration of Mitroflow bioprostheses?
Transcatheter valve-in-valve procedures with balloon-expandable valves provide good mid-term hemodynamic and clinical results for degenerated Mitroflow bioprostheses, though careful assessment is needed to avoid coronary ostial obstruction.
Answers are grounded in this paper and cite their sources.
Requires careful selection to mitigate risks in Mitroflow valve-in-valve; leaves open need for larger comparative studies.
OBJECTIVES: Bioprostheses with pericardial leaflets mounted externally on the stent pose a high risk for valve-in-valve (ViV) procedures. This study analyzed the efficacy and safety of ViV procedures for treating structural valve deterioration (SVD) in Mitroflow bioprostheses. METHODS: Between January 2012 and August 2017, 11 patients (mean age 80.3 ± 5.6 years) were treated for SVD of Mitroflow bioprostheses with transcatheter ViV procedures (six transapical [TA] and five transfemoral [TF]) using balloon expandable bioprostheses. RESULTS: All patients but one were in NYHA class III-IV. Mean STS PROM, euroSCORE I, and euroSCORE II were 8 ± 6.5%, 27.8 ± 11.5%, and 12 ± 5.9%, respectively. Two patients had a "porcelain aorta." The size of implanted valves were 23 mm in 10 cases and 26 mm in one case. One patient suffered a coronary occlusion during a TF approach. The mean volume of contrast used in TF implants was 163 ± 69.8 mL. No contrast media were used in TA procedures. There was one in-hospital death (10%). At 1 year of follow-up, peak and mean aortic gradients were 25.5 ± 5.8 mmHg and 15.5 ± 5.7 mmHg, respectively. One patient had mild paravalvular regurgitation. Cumulative survival was 90.9% at 1 year, 70.7% at 2 years, and 53% at 3 years. CONCLUSIONS: ViV procedures with balloon-expandable aortic valves provide good hemodynamic and clinical mid-term results for treating patients with a degenerated Mitroflow aortic bioprosthesis. Special care must be taken in small aortic roots, when the stented valve is in the supra-annular position to avoid coronary ostial obstruction.
No takes yet. Share an insight, caveat, or question.
Mosquera et al. (2018) conducted an observational in Structural valve deterioration in Mitroflow bioprostheses (n=11). Transcatheter valve-in-valve procedures using balloon expandable bioprostheses was evaluated on Cumulative survival at 1 year. Transcatheter valve-in-valve procedures for structural valve deterioration in Mitroflow bioprostheses resulted in 10% in-hospital mortality and a cumulative survival of 90.9% at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: